[Helicobacter pylori eradication: current status].

Area of Science:

• Gastroenterology
• Infectious Diseases
• Microbiology

Background:

• Helicobacter pylori infection is a global health concern.
• Antibiotic resistance is a growing challenge in H. pylori eradication.
• Optimizing treatment regimens is crucial for successful outcomes.

Purpose of the Study:

• To provide an updated overview of H. pylori eradication therapy efficacy.
• To highlight current first-line and second-line treatment recommendations.
• To address strategies for mitigating antibiotic resistance.

Main Methods:

• Review of current clinical guidelines and research findings.
• Analysis of established and emerging H. pylori eradication regimens.
• Consideration of expert recommendations from gastroenterology associations.

Main Results:

• Triple therapy (proton pump inhibitor + clarithromycin + amoxicillin) remains a leading first-line option.
• Quadruple therapy and 10-day triple therapy with levofloxacin are effective second-line treatments.
• The Russian Gastroenterology Association supports these therapeutic approaches.

Conclusions:

• First-line triple therapy continues to be highly effective for H. pylori eradication.
• Levofloxacin-containing regimens are recommended for second-line treatment.
• Strategic use of clarithromycin (Klacid) is advised to prevent increasing resistance.